MUCOADHESIVE CHITOSAN MICROSPHERES OF GEFITINIB
Objective: Gefitinib, Epidermal Growth Factor-Tyrosine Kinase Inhibitor (EGFR-TKI); has promisingly shown activity against Non-Small-Scale Lung Cancer. Currently, the formulations of this drug available are in Tablets, Capsules and liposomal suspensions taken by the oral route. These have certain disadvantages in gastrointestinal disorders like irritation of GI mucosal layer, bleeding, non-patient compliance and low bioavailability due to low aqueous solubility and thus low bioavailability. The purpose of this study was to formulate and evaluate Chitosan-based Microparticles of Gefitinib for maintaining the therapeutic index and limits its side effects.
Methods: Chitosan microspheres cross-linked with glutaraldehyde were prepared by solvent evaporation technique which is then analyzed for its particle size, encapsulation efficiency, swelling index.
Results: The release rate of the drug can be increased by using chitosan-based carrier system which will enhance its bioavailability. By this work, the anticancer activity of Gefitinib in non-small-scale lung cancer will be successfully determined.
Conclusion: It has been concluded that microspheres can be prepared by solvent evaporation technique by varying the concentration of chitosan and tween-20. Chitosan used in this work is of 85 % degree of deacetylation, 25 % solution of Gluteraldehyde suitable for the formulation of these microspheres. Optimized temperature was selected as 65 Â°C, and the rotation speed was taken as 1200 rpm. Finally, the objectives planned for this research work was performed and evaluated and shown promising results as the dosing frequency is reduced and maximize for 3 d rather than once in a day as per the current formulation available in the market now with a low dosage regimen of 100 mg of dosage strength, administer by pulmonary route. Microparticulate drug delivery system from microspheres is able to deliver the drug in a sustained release manner for the long period of time successfully.
2. Singh MN, Hemant KSY, Ram M, Shivkumar HG. Micro-encapsulation: a promising technique for controlled drug delivery. Res Pharm Sci 2010;5:65-77.
3. Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int J Pharm 2004;282:1-18.
4. Bhavsar MD, Tiwari SB, Amiji MM. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J Controlled Release 2006;110:422-30.
5. He P, Davis SS, Illum L. Chitosan microspheres prepared by spray drying. Int J Pharm 1999;187:53-65.
6. Genta I, Costantini M, Asti A, Conti B, Montanari L. Influence of glutaraldehyde on drug release and mucoadhesive properties of chitosan microspheres. Carbohydrate Polymers 1998;36:81-8.
7. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J Controlled Release 2004;100:5-28.
8. Yu X, Yang G, Shi Y, Su C, Liu M, Feng B, Zhao L. Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance. Int J Nanomed 2015;10:7045.
9. Zhao L, Yang G, Shi Y, Su C, Chang J. Co-delivery of gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance. J Nanobiotechnol 2015;13:57.
10. Zhou X, Yung B, Huang Y, Li H, Hu X, Xiang G, et al. Novel liposomal gefitinib (L-GEF) formulations. Anticancer Res 2012;32:2919-23.
11. Abbas Z, Swamy NGN. Mucoadhesive microspheres as intranasal drug delivery systems: a review. Indian Drugs 2012;49:5-23.
12. Gavini E, Hegge AB, Rassu G, Sanna V, Testa C, Pirisino G, et al. Nasal administration of carbamazepine using chitosan microspheres: in vitro/in vivo studies. Int J Pharm 2006;307:9-15.